ViiV Healthcare v. Hetero Labs: TRIUMEQ Patent Settled via Consent Judgment
ViiV Healthcare, Shionogi, and ViiV Healthcare UK filed suit against Hetero USA and Hetero Labs in the Delaware District Court, asserting US Patent No. 9,242,986 covering the HIV combination therapy TRIUMEQ (dolutegravir, abacavir, lamivudine). The case resolved in 191 days through a negotiated consent judgment that permanently enjoins Hetero from launching its ANDA product without authorization.
Hatch-Waxman ANDA battle over HIV triple-therapy TRIUMEQ ends in injunction
Filed on 3 June 2024 in the Delaware District Court before Judge Mitchell S. Goldberg, this Hatch-Waxman infringement action pitted ViiV Healthcare Company, Shionogi & Co., Ltd., and ViiV Healthcare UK (No.3) Limited against generic manufacturer Hetero USA Inc. and multiple Hetero Labs Limited entities. The plaintiffs asserted US Patent No. 9,242,986, which covers the formulation underlying TRIUMEQ — a once-daily single-tablet HIV regimen combining dolutegravir (50 mg), abacavir (600 mg), and lamivudine (300 mg). Hetero had filed an ANDA seeking to market a generic version of that product.
The case closed on 11 December 2024 via a consent judgment and permanent injunction entered by the court. Under its terms, Hetero and its affiliates, successors, and assigns are enjoined from infringing US9242986 — specifically barred from making, using, selling, offering to sell, importing, or distributing the ANDA product — except as specifically authorised under a confidential Settlement Agreement. All claims, counterclaims, and affirmative defenses were dismissed with prejudice, and each side bears its own legal costs.
At 191 days from filing to consent judgment, the resolution is notably swift for a Hatch-Waxman matter, suggesting the parties identified early common ground rather than litigating through claim construction or trial. The confidential Settlement Agreement likely contains an authorised entry date — the standard commercial lever in ANDA settlements — but that date is not disclosed on the public docket. What remains unknown is whether Hetero secured any launch window, royalty arrangement, or other commercial terms within the sealed agreement.
Filing to Consent Judgment in 191 days
191 days — resolved well under the typical 2–3 year ANDA Hatch-Waxman trial timeline
Consent judgment and permanent injunction: what the resolution means for both parties
Consent judgment is a court-enforceable settlement, not a merits ruling
A consent judgment is a negotiated resolution that carries the full force of a court order. Neither party obtained a judicial finding on infringement or validity — instead, both sides agreed to bind themselves to the settlement terms through the court. Critically, the Delaware District Court retains jurisdiction to enforce the consent judgment, giving ViiV a direct contempt remedy if Hetero launches outside agreed parameters.
No validity rulingUS9242986 survives unchallenged; injunction blocks unauthorised generic entry
ViiV Healthcare and Shionogi secured a permanent injunction against Hetero’s ANDA product without having to prove infringement or defend validity at trial. The patent exits this litigation with no adverse ruling on its claims. Any authorised entry date agreed in the confidential Settlement Agreement gives ViiV control over the timing of generic competition — a commercially significant outcome for a high-revenue HIV combination product.
Patent enforceability intactHetero enjoined from launch except as permitted by sealed settlement
Hetero consented to a permanent injunction and dismissed all counterclaims and invalidity defenses with prejudice, foreclosing any future re-litigation of those positions in this venue. The sealed Settlement Agreement likely provides a negotiated authorised entry date, which is the primary commercial concession generic manufacturers seek in ANDA consent judgments. The absence of any public cost award suggests the settlement was genuinely bilateral.
Launch date likely sealedTRIUMEQ exclusivity reinforced; market entry timeline under ViiV’s control
TRIUMEQ is one of the most commercially significant HIV combination therapies globally. A consent judgment blocking Hetero’s ANDA — with no validity challenge surviving — reinforces ViiV’s market position for the remaining life of US9242986. Other ANDA filers or potential challengers will note that Hetero did not extract a public invalidity finding, raising the cost and uncertainty of any future challenge to this patent family.
Generic competition deferredFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ViiV Healthcare, Co. | Company | Global HIV pharmaceutical company — holder of US9242986 covering TRIUMEQ combination therapySearch in Eureka ↗ |
| Co-Plaintiff | Shionogi & Co., Ltd. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Viiv Healthcare UK (No.3) Limited | Individual | Search in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | Indian generic pharmaceutical manufacturer and its US subsidiary seeking ANDA approval for TRIUMEQ equivalentSearch in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for ViiV Healthcare, Co.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for ViiV Healthcare, Co.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing ViiV Healthcare, Co.Search in Eureka ↗ |
| Defendant counsel | Cortlan S. Hitch | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Mitchell S. Goldberg | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment language is carefully structured to preserve ViiV’s enforcement leverage while keeping commercial terms confidential. The permanent injunction covers Hetero’s entire corporate family — affiliates, successors, and assigns — closing structural workarounds. The phrase ‘except as specifically authorized pursuant to the Settlement Agreement’ is the operative carve-out that governs any licensed generic launch window. Because all counterclaims were dismissed with prejudice, no invalidity or non-infringement finding appears on the record, leaving US9242986’s validity legally uncontested.
US9242986B2 — TRIUMEQ HIV triple-combination tablet formulation
US Patent No. 9,242,986 (application no. US14/272823) covers the formulation of TRIUMEQ, a once-daily fixed-dose combination tablet containing dolutegravir sodium (equivalent to 50 mg base), abacavir sulfate (equivalent to 600 mg base), and lamivudine (300 mg). Dolutegravir is an integrase strand transfer inhibitor (INSTI), and its co-formulation with the nucleoside reverse transcriptase inhibitors abacavir and lamivudine represented a significant advance in simplifying HIV antiretroviral therapy to a single daily tablet. The patent is assigned to ViiV Healthcare UK and co-owned with Shionogi, reflecting the collaborative discovery of dolutegravir.
TRIUMEQ has been one of the highest-revenue HIV products globally, making US9242986 a high-value enforcement asset. The patent’s survival through this ANDA litigation — with no adverse claim construction, invalidity finding, or post-grant challenge reflected on the public record — strengthens ViiV’s position against subsequent ANDA filers. For generic pharmaceutical companies with active or planned ANDA filings for dolutegravir-containing combination products, this outcome signals that patent challenge litigation carries meaningful risk and that settlement with a negotiated entry date may be the commercially rational path.
Should your team run an FTO analysis against US9242986?
Any generic pharmaceutical company, contract development and manufacturing organisation (CDMO), or formulation developer working on fixed-dose combination antiretroviral tablets — particularly those containing dolutegravir, abacavir, or lamivudine — should treat US9242986 as a primary FTO consideration. The consent judgment in this case confirms the patent is actively enforced and that ViiV will pursue injunctive relief swiftly. Companies planning ANDA filings, 505(b)(2) applications, or international generic registrations for TRIUMEQ equivalents face direct exposure.
PatSnap Eureka’s FTO Search Agent enables R&D and regulatory teams to map the full US9242986 patent family, identify claim scope boundaries, locate potential design-around opportunities, and monitor continuation or divisional applications that may extend exclusivity. Eureka’s litigation intelligence layer cross-references active ANDA cases and consent judgments, so your team can benchmark settlement patterns and model entry timing — without starting from a blank docket search.
Run a freedom-to-operate analysis on US9242986B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: HIV combination therapy litigation in Delaware
Explore comparable Hatch-Waxman ANDA infringement cases involving HIV antiretroviral combination therapies litigated in the Delaware District Court.
What this case signals for the HIV pharmaceutical IP landscape
A swift ANDA consent judgment with full injunction reinforces branded HIV combination therapy exclusivity and sets a visible precedent for Hetero’s ANDA peers.
Early ANDA settlements with injunctions are increasingly the norm in HIV IP
Resolving in under 200 days — before claim construction — this case is consistent with a broader trend of branded HIV manufacturers securing consent judgments that preserve exclusivity without the litigation risk of a validity trial. For other ANDA filers targeting TRIUMEQ, the absence of any successful invalidity challenge here raises the threshold for a competing generic strategy.
Permanent injunction without merits ruling limits Hetero’s future freedom to operate
By dismissing counterclaims with prejudice, Hetero waived invalidity and non-infringement arguments in this forum. While that does not technically bar an IPR petition at the USPTO, it signals that Hetero chose commercial negotiation over patent challenge — a choice that strengthens US9242986’s perceived enforceability in the eyes of other potential challengers.
ViiV v Hetero — key questions answered
The case resolved on 11 December 2024 via a consent judgment and permanent injunction. Hetero and its affiliates are enjoined from infringing US Patent No. 9,242,986 by making, selling, or importing the ANDA product except as permitted under a confidential Settlement Agreement. All claims were dismissed with prejudice, with no costs awarded to either party.
ViiV Healthcare, Shionogi & Co., and ViiV Healthcare UK (No.3) asserted US Patent No. 9,242,986 (application no. US14/272823), which covers the fixed-dose combination formulation underlying TRIUMEQ — a once-daily HIV tablet containing dolutegravir sodium (50 mg), abacavir sulfate (600 mg), and lamivudine (300 mg).
The injunction covers Hetero USA Inc., Hetero Labs Limited, and all their affiliates, successors, and assigns. It bars making, having made, using, selling, offering to sell, importing, or distributing the ANDA product that is the subject of the action, except as specifically authorised under the confidential Settlement Agreement. The Delaware District Court retains jurisdiction to enforce compliance.
No judicial finding on validity or infringement was made. The case resolved through a negotiated consent judgment before any merits ruling. Hetero’s counterclaims and affirmative defenses — which would typically include invalidity arguments — were dismissed with prejudice, meaning the patent exits this litigation with no adverse ruling on its validity or enforceability.
At 191 days from filing to consent judgment, the case resolved well before claim construction or trial — typical Hatch-Waxman cases can take two to three years. The swift resolution suggests the parties identified common commercial ground early, most likely involving a confidential authorised generic launch date in the Settlement Agreement. Neither side faced the cost and uncertainty of a contested validity trial.
PatSnap Eureka searches patents and litigation data to answer instantly.